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Tuberculosis (TB) is a major health issue globally. Although typically the disease can be
cured by chemotherapy in all age groups, and prevented in part in newborn by vaccination,
general consensus exists that development of novel intervention measures requires bet-
ter understanding of disease mechanisms. HumanTB is characterized by polarity between
host resistance as seen in 2 billion individuals with latent TB infection and susceptibility
occurring in 9 million individuals who develop active TB disease every year. Experimental
animal models often do not reflect this polarity adequately, calling for a reverse transla-
tional approach. Gene expression profiling has allowed identification of biomarkers that
discriminate between latent infection and active disease. Functional analysis of most rel-
evant markers in experimental animal models can help to better understand mechanisms
driving disease progression. We have embarked on in-depth characterization of candidate
markers of pathology and protection hereby harnessing mouse mutants with defined gene
deficiencies. Analysis of mutants deficient in miR-223 expression and CXCL5 production
allowed elucidation of relevant pathogenic mechanisms. Intriguingly, these deficiencies
were linked to aberrant neutrophil activities. Our findings point to a detrimental potential
of neutrophils in TB. Reciprocally, measures that control neutrophils should be leveraged
for amelioration of TB in adjunct to chemotherapy.
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INTRODUCTION
Until today, segregation between basic and applied research has
not been fully overcome in medical science, including immunol-
ogy. Principally, basic research is conceived as hypothesis-driven,
which benefits from choice of the most suitable experimental
approach. Successful studies end with an outlook on medical appli-
cation. In rare instances when this outlook indeed materializes,
the whole endeavor is considered a perfect example of transla-
tional medicine. In contrast, applied clinical research is hampered
by various layers of complexity, including heterogeneity of human
populations and limitations in experimental approaches.
Recent advances in “omics” (i.e., high-throughput, HT,
approaches, such as genomics or transcriptomics) have allowed
a reciprocal strategy related to data-driven and hypothesis-
generating approaches, which have been recognized as valuable
complements to the hypothesis-driven path (1). Comparative
studies of patients and healthy controls using different omics
readouts allow a deeper understanding of mechanisms underly-
ing disease progression, and identification of thus far unknown or
insufficiently understood biological functions (2, 3). Hence, new
research questions can be formulated, based on findings in the
clinical context, which can subsequently be dissected in appropri-
ate experimental models (Figure 1) – in short, from the bed to the
bench (4).
Immunology of tuberculosis (TB) is a case in point: mech-
anisms underlying pathology and protection in TB are highly
intertwined and quantitative rather than qualitative differences
tip the balance toward disease progression (5). We have embarked
on analyzing biomarkers that distinguish TB patients from healthy
individuals and identified markers, which have fueled our interest
to better understand their biological functions in TB.
THE ISSUE: TUBERCULOSIS
With a morbidity of 8.6 million cases and a mortality of 1.3 million
deaths annually, TB remains a major health issue, surpassed only
by human immunodeficiency virus/acquired immune deficiency
syndrome (HIV/AIDS) (6, 7). In fact, the two diseases have joined
forces to create a perfect storm: TB is the major cause of death of
HIV-infected individuals and HIV/AIDS the driving force for TB
reemergence (6). Infection with Mtb transforms into active dis-
ease in only 5–10% resulting in 2 billion individuals with latent
TB infection (LTBI), who remain healthy. Immunity is orches-
trated by T lymphocytes that activate anti-mycobacterial activities
in infected macrophages (5, 8). This is a local event focused on
granulomatous lesions. Mtb is efficiently contained in solid gran-
ulomas where it adopts a dormant stage characterized by low
replication rate and minimal metabolic activity (9, 10).
Globally, the ca. 2 billion healthy individuals with LTBI main-
tain this stage by means of an active immune response (5, 8).
Yet, once it deviates, active disease develops. This is preceded by
increasing necrosis of the granuloma followed by liquefaction.
In the caseous granuloma, Mtb is resuscitated and resumes high
replicative and metabolic activity (9, 10). Often in TB patients,
granulomas of different maturation stages coexist (11). Whilst in
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FIGURE 1 | Iterative cycle between translation and reverse
translation inTB research and development. Canonical science
frequently follows translational pathways from basic research to clinical
studies (pro for basic research as starting point: hypothesis-driven proof
of principle; con: dissociation of hypothesis from real-life). In this way,
proof of principle derived from basic research can be validated under
real-life conditions. Increasingly, reverse translation of clinical
observations into hypothesis generation is pursued (pro for clinical
studies as starting point: reality-driven hypothesis generation; con:
generation of questions without direct answers). Clinical studies and
trials generate “real-life” data, which are subsequently tested and
verified by basic research. This allows for validation of reality-driven
questions raised in clinical studies. An iterative correlation of
hypothesis-driven and data-driven research in the clinical context, with
the help of computational analyses, will accelerate both generation of
knowledge and design of novel intervention measures.
some granulomas the immune response is still capable of con-
trolling Mtb, in others, it has already failed and Mtb has mastered
the battle field (9, 10). Divergent immune activities in different
lesions create major obstacles in the analyses of relevant immune
responses in the periphery: it is likely that the circulating leuko-
cytes reflect an averaged dominant stage of immune defense,
but not unique activities operative in different lesions of varying
immune status.
In infants, serious forms of TB can be prevented by vaccination.
The vaccine, bacille Calmette–Guérin (BCG), therefore is still part
of vaccination programs in countries where TB is endemic (12).
Today, BCG is the most widely used vaccine with at least 4 billion
total, and ca. 100 million annual, administrations. Yet, an effica-
cious vaccine against pulmonary TB in all age groups, which is
not only the most prevalent form, but also the major source of
transmission, is not available. Currently, novel vaccine candidates
are being developed of which more than a dozen are undergoing
clinical evaluation (13).
Tuberculosis can be cured by chemotherapy. However, suc-
cessful treatment is long-lasting, requiring three to four drugs
given over a period of at least 6 months. Not the least due to
the complex and long-lasting treatment regimen, resistant TB is
on the rise (14–16). Fifty million individuals are infected with
multidrug-resistant (MDR)-Mtb strains that cannot be treated
adequately with first-line drugs. Therefore, for half a million new
MDR-TB cases annually, second-line drugs requiring longer and
more complex treatment schedules with higher side effects must
be employed. The ca. 50,000 individuals registered in 92 coun-
tries, who have developed extensively drug-resistant (XDR)-TB,
are even worse off since this form of TB is almost untreatable (6).
In the meantime, totally drug-resistant (TDR)-TB has been noti-
fied in countries in Asia, Europe and Africa. No drugs are available
to treat this form of TB. As a corollary, cost for TB control is
increasing. It has been estimated that the European Union invests
more than half a billion C for TB control and that the real cost
including loss of human capital is in the order of 6 billion C (17).
Globally, somewhere between 20 and 200 billion US$ are lost due
to TB, resulting in 0.5% loss of gross national income.
The epidemiologic facts of 1.3 million deaths and 8.6 million
new cases of TB annually, may be viewed as perplexing in the
face of 2 billion healthy individuals with LTBI. This conundrum
immediately raises the question: what is the difference between
individuals who successfully control one of the most devastat-
ing pathogens, whilst others succumb? This enigma is difficult
to study in experimental animal models, which, aside from non-
human primates, do not reflect the dissociation between LTBI and
active TB disease adequately. At the same time, modern HT gene
expression profiling of peripheral blood leukocytes could allow a
gateway toward the elucidation of gene products involved in resis-
tance underlying LTBI and pathology present in active TB. We
launched a critical analysis of biomarkers that distinguish patients
with active TB from healthy individuals with LTBI and selected
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markers of interest for in-depth analyses in experimental mouse
models.
BIOSIGNATURES, BIOMARKERS AND REVERSE
TRANSLATION
The past decade has witnessed increasing interest in biomarker
research in the area of TB. The potential of these biomarkers ranges
from differential diagnosis to predictive response to therapy and
risk to disease progression (2, 3). Biomarkers will also play a cru-
cial role in future vaccine and drug trial design (18–20). On top of
this, omics marker research can provide a wealth of information,
which can be further exploited to decipher underlying resistance
and disease mechanisms.
Principally, biomarker research is set in a clinical context and
seeks to answer questions such as: How to diagnose or predict
disease? How to monitor treatment outcome? How to predict
vaccine efficacy and safety? Thus, large-scale HT platforms have
been launched with the goal of screening thousands of genes or
hundreds of metabolites [for a review see Ref. (2)]. From these
studies the view emerges that quantitative biosignatures, rather
than individual,“on-off” biomarkers are informative predictors of
disease progression, treatment outcome or vaccine efficacy/safety.
Basically, mere presence or absence of a single gene in a biosig-
nature is insufficient to achieve error rates below 10%. Rather,
relative expression levels of a set of genes or abundances of a set
of metabolites form a more informative multidimensional biosig-
nature. Metaphorically, instead of a single decision maker (i.e., a
single biomarker), we view a biosignature as a house of represen-
tatives that agree on a mechanism, state of disease, or outcome of
an intervention by casting a majority vote.
The primary goal of attempts to define biosignatures remains in
the clinical arena. Yet, added to this, the functional interpretation
of biosignatures allows precious insights into the pathophysiol-
ogy of TB, as well as the generation of specific hypotheses to be
tested in an experimental setting (3, 21). Vice versa, identifying
relevant biological processes can clearly drive the search for useful
biomarkers (22). Biomarkers should thus not be viewed as a com-
putational black box that exists outside of biology; rather, they can
both drive, and profit from, specific hypothesis-driven research.
Whole genome expression profiling by microarray analysis of
peripheral blood cells, which has been applied most widely (23–
30), provides a large body of data tempting researchers to formu-
late novel hypotheses. Prominent in peripheral blood, active TB
disease is reflected by an increased activity in interferon (IFN) sig-
naling, mainly in circulating neutrophils (23). In a similar fashion,
most studies on blood cells have identified up-regulated signaling
through Fc gamma receptors and elevated activity of the comple-
ment system [Ref. (23–25, 29, 31), for a review see Ref. (2)]. Finally,
several publications describe activation of the Janus kinase-signal
transducer and activator of transcription (JAK-STAT) pathway
(23–25), and abnormal functionality of regulatory suppressors of
cytokine signaling [SOCS3, Ref. (27)] in TB. Such findings point to
dysregulation in several key biological pathways, marking chronic
immune activation and immune pathology of TB disease. The bio-
marker studies performed over the past years have revealed several
TB-related signatures as described herein. The current challenge
is to identify markers that are specific and unique for TB (for
a short listing of markers in TB and other pulmonary diseases;
see Table 1). For example, the first “TB-specific” signature iden-
tified in a comparison with other infectious diseases (23), turned
out shortly afterward to be also present in sarcoidosis (26, 32),
which has high clinical similarity to TB. Elevated IFN-signaling,
Fc gamma receptor signaling and complement activation are also
shared with other respiratory diseases (26, 32, 33). A recent study
(34) identified blood transcriptome signatures that were identified
in both HIV− and HIV+ donors. Such findings are encourag-
ing that future TB-specific signatures could also be applied in
HIV-endemic countries.
Although signatures, as described above, are related to elevated
anti-microbial activities of the immune response, they can also
have detrimental effects. One informative example is the pre-
ponderant role of IFNs in the inflammation sustained during TB
disease. While the role of type II IFN (IFN II or IFN-γ) in protec-
tion against TB is well established (35, 36), the role of type I IFN
(IFN I) is less clear. Rather IFN I responses have been generally
associated with anti-viral defense (37). Yet, both IFN I and IFN
II signaling pathways are markedly up-regulated in TB. This led
several groups to embark on analysis of IFN I in experimental TB
and investigate interference between IFN I and II in mycobacterial
infections.
IFN I CROSS-REGULATES CYTOKINE NETWORKS IN TB
Non-redundant functions have been attributed to IFN I and II
during pulmonary TB in TB-resistant mice (38). Both cytokines
contribute to adequate differentiation, survival and/or recruit-
ment of myeloid cells to the lungs early during infection. Anti-
inflammatory roles affecting leukocyte recruitment were uncov-
ered in animals with intact IFN I signaling. These observations,
however, contrast data obtained with animals receiving IFN I
inducers (39), which develop exacerbated lung inflammation.
Others have proposed that similarly to IFN II, IFN I limits avail-
ability of IL-1, a key pro-inflammatory cytokine (40, 41). The
anti-inflammatory roles of IFN I in murine TB, as described for
TB-resistant mice, are partially in line with results recorded for
acute bacterial infections (42). Yet, these effects are opposed to
those reported for chronic insults and infections (43, 44), which
are characterized by IFN I-triggered inflammation. These appar-
ently contradictory findings suggest biphasic and perhaps context-
specific activity of IFN I. In support of this notion, investigations
focusing on lymphocytic choriomeningitis virus (LCMV) infec-
tion describe a paradoxical detrimental role of IFN I during the
chronic phase of this viral disease (45, 46).
In addition, cross-regulation between IFN I and II was revealed
during mycobacterial infection, thereby explaining, to some
extent, divergent observations. Via IL-10, IFN I regulates expres-
sion of the receptor for IFN II and subsequently cellular respon-
siveness to protective IFN-γ (47). On the other hand, absence of
the IFN I-inducible ubiquitin-like intracellular protein ISG15 lim-
its release of IFN II (48). It appears that both positive and negative
regulation loops between IFN I and II exist and additional regula-
tory check points will likely be identified in the future. Although
considerable progress has been achieved to streamline the bio-
marker value of IFN I, there is still need to decipher in greater
detail local and perhaps systemic effects of IFN I signaling in TB.
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Table 1 | Genes identified as differentially expressed inTB compared to healthy controls and reported as a part of a biosignature.
Interferon
signaling
Pattern recognition
receptor and inflammation
Neutrophil
response
Adaptive
immunity
Chemokines and
receptors
Complement
system
Fc receptors Other
IFIT2; 3 (s) TLR5 (sa; l) MPO (p) BATF2 (s) CXCR3 (s) C1QA CD64 (s; p; l) RAC1 (s)
IFI44L (s) CD32 (s) CTSG (sa) CD4 CXCR4 (s) C1QB (sa) CD32 (s) SEC14 (s)
GBP1; 2; 5; 6 (s) IRAK1; 3; 4 (s) LTF (s; p) CD40 (s) CXCR5 (s) C2 KLF2 (sa)
OAS1 (sa) ETS2 (s) BPI (sa) IGHM (s) CXCL9 (s) SERPING1 (s) HIF1A (s)
SOCS1 (s) NAMPT (s; p) DEFA4 (p) IGHD (s) CXCL10 (s) HLTF (s)
SOCS5 (s) CD163 (s; l) NCF1 (s) IGJ CXCL14 (sa) PSMA 1–7 (s)
TGFB1 (s) LCN2 CCL23 (s) UCN2 (s)
TRAF5 MMP9 (s; l; p) SMARCD3 (s)
MMP8 (p) FOXB1
FOXC2
TIMP (s)
RAB13 (sa; p)
RAB33 (s)
CASP8 (s)
Annotations in brackets denote whether a gene has also been reported as differentially expressed in another disease condition by Maertzdorf et al. (26) or Bloom
et al. (32); s, sarcoidosis; p, pneumonia; l, lung cancer.
aDenotes genes that, while identified as differentially expressed in sarcoidosis, differ significantly in their expression from TB.
miR-223 FINE-TUNES INFLAMMATION IN TB
In the beginning, gene expression profiling mainly targeted
protein-coding genes. More recently, the potential value of
microRNAs (miRs), as TB biomarkers, has gained increasing inter-
est (49) (Table 2). miRs have a profound impact on the biological
activity of proteins by regulating messenger RNA (mRNA) sta-
bility and translation (50). Parallel analysis of miRs and mRNAs
revealed significant correlations between expression of protein-
coding and regulatory small miRs, suggesting functional relevance
in TB (26). Particular miRs have been tentatively identified as
potential biomarkers based on their differential expression levels
(51–55). Moreover, by means of HT analyses of TB mRNAs and
miRs, we identified clusters of correlated miRs and mRNAs, which
were differentially expressed between TB and controls (2, 26) and
enriched for immune-related functions. Their direct biological
function in TB, however, remains largely elusive. Whereas miRs
are generally considered to fine-tune mRNA expression rather
than performing unique functions, we recently demonstrated a
unique biological role of one such miR in inflammatory processes
in TB (56).
In our studies, we focused our attention on miR-223, which
had been identified in one study as one of the most up-regulated
miRs in peripheral blood of patients with active TB compared to
individuals with LTBI (54). MiR-223 expression is induced during
granulopoiesis (60), controlled by different myeloid transcription
factors (61, 62), and reaches its highest level in mature neutrophils.
Additionally, miR-223 modulates cell activation by targeting NLR
family pyrin (NLRP) containing domain 3 (NLRP3) inflamma-
some and I-kappa-B-kinase (IKK) alpha (IKK-α) (63, 64). To
address the biological role of miR-223 during TB, we employed
the aerosol Mtb infection model of miR-223 mutant mice (60).
MiR-223-deficient mice were highly susceptible to pulmonary TB.
Lethality was preceded by profound alteration of the lung struc-
ture, high bacterial burden, and exacerbated inflammation, which
Table 2 | Candidate microRNA biomarkers for activeTB.
Sample type microRNA Reference
Monocytes hsa-mir-582-5p (57)
CD4+ T cells has-miR-21, has-miR-26a,
has-miR-29a, and miR-142-3p
(52)
Serum hsa-miR-361-5p, hsa-miR-889,
and miR-576-3p
(53)
PBMCs hsa-miR-146a and has-miR-424 (58)
Sputum hsa-mir-3179, has-miR-147, and
hsa-miR-19b-2-5p
(55)
Peripheral whole blood hsa-miR-144 (26)
PBMCs hsa-miR-155 and hsa-miR-155-3p (59)
PBMCs hsa-miR-144, hsa-miR-365,
hsa-miR-424, and hsa-miR-451
(54)
Serum hsa-miR-29a (51)
was mostly due to uncontrolled neutrophil migration to the site
of infection. Lung gene expression profiling highlighted genes
involved in neutrophil recruitment and the immune response as
potential targets for miR-223.
Corroboration of gene expression profiles with predicted tar-
gets of miR-223, combined with molecular investigations, allowed
us to identify chemokine (C-X-C motif) ligand 2 (CXCL2),
chemokine (C-C motif) ligand 3 (CCL3), and interleukin 6 (IL-6)
as novel targets of miR-223. These proteins were abundant during
Mtb infection and directed neutrophil activation, and/or recruit-
ment. Indeed, CXCL2 and CCL3 were first identified as chemotac-
tic molecules for neutrophils produced by activated macrophages
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while IL-6 regulates granulopoiesis (65–67). Thus, in our model
of experimental TB, the absence of miR-223 was responsible for
uncontrolled expression of chemotactic mediators, CXCL2 and
CCL3, and heightened neutrophil availability due to impaired
granulopoiesis as a consequence of uncontrolled IL-6 expression.
These conditions, concurrent with more abundant chemokine (C-
X-C motif) receptor 2 (CXCR2) expression (60), were responsible
for impaired neutrophil migration to the lung during TB and
consequently tissue destruction.
These results add further knowledge to the role of miRs during
TB and in particular suggest that miR-223 controls TB suscep-
tibility by limiting neutrophil recruitment through regulation of
pro-inflammatory chemokines.
CHEMOKINE-DEPENDENT NEUTROPHIL INFLUX MODULATES
TB PATHOLOGY AND SUSCEPTIBILITY
Our biomarker analysis focusing on miR-223 in experimental TB
of mice as well as reports by others reveal a profound correla-
tion between disease susceptibility, TB pathology, and magnitude
of the neutrophil responses. DBA/2, CBA/J, and C3HeB/FeJ, all
Mtb-susceptible mouse strains, suffer from increased pulmonary
neutrophil influx (68–70). Treatment of these animals with anti-
inflammatory agents alone or combined with anti-mycobacterial
chemotherapy limits progression of active TB (70, 71), suggesting
that targeting neutrophilic inflammation is a valid option for cure
of TB. Likewise, susceptible gene-deletion mutant strains, such
as Card9−/− and miR-223−/− mice can be rescued by antibody-
mediated neutrophil depletion (56, 72). In patients with pul-
monary TB, neutrophils are abundant in BAL fluid and sputum
and show higher bacterial burden than macrophages (73). The
potential beneficial role of neutrophils in TB through killing the
pathogen remains a matter of debate. Reports on a role of neu-
trophils in human TB range from assigning them solely phagocytic
capacities to Mtb-killing capacities (74). In the zebrafish model,
neutrophils kill M. marinum by engulfing-infected macrophages
(75). In mice, immune-advantageous functions of neutrophils in
TB have been linked to dendritic cell migration and T cell priming
(76, 77).
Neutrophils can rapidly enter sites of inflammation under the
direction of humoral factors including chemokines, notably of the
ELR+ CXC family, which bind to CXCR1 and CXCR2. ELR− CXC
chemokines, for example, CXCL13, are primarily chemoattrac-
tants for lymphocytes and bind to CXCR3, CXCR4, CXCR5, and
CXCR7. Further subfamilies, include the CC chemokine subfam-
ily, which comprises various members and bind to CC receptors;
their target cells include most types of leukocytes. The third and
fourth chemokine subgroups contain few members: the (X)C
chemokine family consists of XCL1 and XCL2, and both primarily
target T cells expressing the receptor XCR1. The CX3C chemokine
subfamily comprises to date only one known member, CX3CL1,
which serves in its soluble form as chemoattractant for T cells
and monocytes and in its cell-bound form as adhesion molecule
[reviewed in Ref. (78, 79)].
To better understand how excessive neutrophil influx partic-
ipated in increased TB susceptibility, we embarked on study-
ing the role of CXCR2/CXCL5 in neutrophil control. Dif-
ferent chemokine/chemokine receptor pairs and inflammatory
mediators are described to be involved in neutrophil influx into the
lung (80). However, we and others had noted that the neutrophil-
chemotactic receptor, CXCR2 and its ligand, CXCL5 [or LPS-
induced CXC chemokine (LIX)] are strongly up-regulated early
following Mtb infection (69, 78, 81). Other ligands of CXCR2 com-
prise ELR+ chemokines, such as CXCL1 [or keratinocyte-derived
chemokine (KC)], CXCL2 [or macrophage inflammatory protein
2 (MIP-2)], and CXCL15 (or lungkine).
The potential of chemokines and their receptors in shaping
immune responses against Mtb have thus far focused on lympho-
cyte recruitment and granuloma organization (78). The influence
of the chemokine system on neutrophil responses and inflam-
mation in TB is poorly characterized. CXCR2−/− mice show nor-
mal pulmonary neutrophil influx following intratracheal infection
with an atypical Mycobacterium, M. avium. After intraperitoneal
challenge with M. avium, however, neutrophil recruitment was
impaired in CXCR2−/− mice albeit without affecting bacterial
burden (82). We found that following aerosol Mtb infection, neu-
trophil influx into alveolar spaces depended on CXCR2 as well as
CXCL5. Moreover, absence of either CXCR2 or CXCL5 rendered
mice more tolerant to high-dose Mtb infection (83).
Since multiple chemokines can bind CXCR2, they have gener-
ally been regarded as redundant. However,kinetic analyses indicate
their temporal regulation (78) and cell type-specific expression
of different chemokines points toward their spatial regulation.
In TB, lung epithelial cells served as the pulmonary source of
CXCL5 (83). Neutrophil-attracting chemokines including CXCL2
and CXCL1 are abundantly secreted by macrophages and neu-
trophils. CXCL1, but not CXCL2, is also secreted by pneumocytes.
CXCL15 is solely secreted by bronchial epithelial cells (80, 84).
CXCL5 is produced by platelets and various tissue-resident cells,
such as alveolar epithelial cells (85, 86), cardiac myocytes (87),
enterocytes (88), and aortic endothelial cells (89).
Taking the pathologic potential of dysregulated neutrophil
responses into account, it appears essential that the host employs
mechanisms to tightly regulate their recruitment into sensitive
tissues. We propose that one mechanism is the temporal and
spatial regulation of neutrophil-attracting chemokines. Thus,
rather than being redundant, we suggest that neutrophil-attracting
chemokines targeting the same receptor express unique, often
additive effects.
CONCLUDING REMARKS
Tuberculosis biomarker research continues to generate signa-
tures with clinical applicability and additionally furnishes novel
hypotheses related to disease pathophysiology. We followed several
candidate pathways and molecules that emerged from transcrip-
tomics studies, including miR-223. Murine experiments provided
deeper insights into disease processes influenced by this mole-
cule. Neutrophils represented key effector cells of pathogenesis.
In a complementary approach, we investigated the pathways that
control neutrophil recruitment to the lung in progressive TB
and distinguished a hitherto unappreciated relevance of a unique
chemokine, namely CXCL5.
These examples illustrate that reverse translation is a valid
approach and perhaps most importantly that iterative cross-
examining of basic research findings and patient “omics” data,
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allows novel insights into TB pathogenesis. We envisage that
additional aspects of disease pathophysiology will be uncovered
by integrating information from multiple patient-driven HT stud-
ies, such as metabolomics, proteomics, lipidomics along with
transcriptomics, and deep-sequencing. In a further step, host
information could be complemented by pathogen screens. This
strategy will facilitate insights into host–pathogen interplay and
allow prediction of interaction algorithms to be experimentally
validated. As TB vaccine research and development suffer from
lack of rigorous correlates of protection, we propose that reverse
translation can significantly contribute to better understanding of
basic mechanisms underlying pathophysiology. Such an approach
will not only form the basis for identification of biosignatures
that predict risk of disease but also predict vaccine efficacy. In
a similar vein, biosignatures derived from TB vaccine trials can
provide novel insights into vaccine-induced protective mecha-
nisms. The feasibility of such an approach has proven successful
in trials with licensed vaccines (18). Reciprocally, experimental
TB research can facilitate rational design of novel intervention
measures.
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